Clarithromycin
NDC Package 67296-0464-1
Package Information
Clarithromycin is 1.1 Acute Bacterial Exacerbation of Chronic BronchitisClarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Indications and Usage (1.9)].1.2 Acute Maxillary SinusitisClarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Indications and Usage (1.9)].1.3 Community-Acquired PneumoniaClarithromycin tablets are indicated [see Indications and Usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to:• Haemophilus influenzae (in adults) • Mycoplasma pneumoniae, Streptococcus pneumoniae, Chlamydophila pneumoniae 1.4 Pharyngitis/TonsillitisClarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Streptococcus pyogenes as an alternative in individuals who cannot use first line therapy.1.5 Uncomplicated Skin and Skin Structure InfectionsClarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Staphylococcus aureus, or Streptococcus pyogenes.1.6 Acute Otitis MediaClarithromycin tablets are indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Clinical Studies (14.2)].1.7 Treatment and Prophylaxis of Disseminated Mycobacterial InfectionsClarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Mycobacterium avium or Mycobacterium intracellulare in patients with advanced HIV infection [see Clinical Studies (14.1)].1.8 Helicobacter pylori Infection and Duodenal Ulcer DiseaseClarithromycin tablets are given in combination with other drugs in adults as described below to eradicate H. Marketed by Redpharm Drug, Inc., this product is identified by NDC 67296-0464 and is authorized under FDA application ANDA065136.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 67296 - Redpharm Drug, Inc.
- 67296-0464 - Clarithromycin
- 67296-0464-1 - 20 TABLET in 1 BOTTLE
- 67296-0464 - Clarithromycin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 67296-0464-1 identifies a specific commercial package of 20 tablet in 1 bottle of Clarithromycin, labeled by Redpharm Drug, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Redpharm Drug, Inc. on August 25, 2005. The current certification is valid through December 31, 2025.
How is this Redpharm Drug, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 67296046401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.